-
Dr Boreham’s Crucible: Sizing up the opportunity for ASX biotech Adherium
16 Jun 2025 20:19 GMT
…
Children might spray the treatment like a perfume and … trials. In 2009, it won US Food and Drug Administration (FDA) … Ellipta and Astrazeneca’s Symbicort.
The Bluetooth-enabled Hailies … qualified medical practitioner and does not possess a doctorate of …
-
Hepion Pharmaceuticals Announces Dr. Kaouthar Lbiati as Interim Chief Executive Officer
16 Jun 2025 12:30 GMT
… in both biotech and large pharmaceutical companies. She … areas including regenerative medicine. She has led … treatments including Jevtana®️, Votrient®️, Blincyto®️, Filgotinib®️, and Symbicort®️, … knowhow, clinical trial data and drug product relating to …
-
Triple-Combination Therapy Met Primary End Point in Phase 3 Trials, Providing Treatment for Individuals With Asthma
20 May 2025 18:22 GMT
… Kalos (NCT04609878) and Logos trial (NCT04609904) among individuals … “Despite advancements in asthma treatments, millions of patients remain … fumarate (PT009 and Symbicort pMDI).1
A total … medical meetings.1
“The results from the KALOS and LOGOS trials …
-
Trust Specialist Hospital, AstraZeneca push asthma breakthrough with symbicort access
13 May 2025 20:13 GMT
… the role of symbicort in the treatment of asthma, which … our public health personnel – our doctors, nurses, community health nurses … effectively,” she concluded.
A medical representative from AstraZeneca, Dorothy … all this and our drug is not accessible to …
-
Generic Drugs Market size is projected to reach USD 594.99 billion by 2031, With growing at a CAGR of 5.0% | The Insight Partners
09 May 2025 14:31 GMT
… generic drugs market is segmented into antidepressants, … Pharmaceutical Market, Oncology Drugs Market, Antibiotics Market, OTC Drugs Market, Prescription Drugs … medicines. The increasing patent expiry for cancer drugs, anti-diabetic drugs, and treatments …
-
Breztri for asthma meets primary endpoints in two phase 3 trials
08 May 2025 18:16 GMT
… each trial) with uncontrolled asthma to determine how treatment with … told Healio. “The medicine remains the fastest growing … the KALOS and LOGOS trials include two comparator groups. … pressurized metered-dose inhaler (Symbicort, AstraZeneca).
In addition to …
-
AstraZeneca's fixed─dose triple─combination therapy, Breztri meets primary endpoints in KALOS & LOGOS phase III trials in asthma
03 May 2025 05:07 GMT
… as a potential treatment for asthma. The trials evaluated the … of standard of care medicines and continue to experience … an Aerosphere inhaler) and Symbicort pressurised metered-dose inhaler ( … 400 randomised patients.
The trial design was optimised to …
-
AstraZeneca's Breztri aces 2 asthma trials, lining it up for label expansion
02 May 2025 18:30 GMT
… .
Two phase 3 trials evaluating the effectiveness and … presented at an upcoming medical meeting, the company added … “Despite advancements in asthma treatments, millions of patients remain … combination of AZ’s blockbuster Symbicort (budesonide/formoterol), …
-
BREZTRI met primary endpoints in KALOS and LOGOS Phase III trials in asthma
02 May 2025 11:21 GMT
… potential treatment for asthma.1,2 The trials evaluated … oxidase inhibitors and tricyclic antidepressants, as these may … an AEROSPHERE inhaler) and SYMBICORT pressurized metered-dose inhaler … and commercialization of prescription medicines in Oncology, Rare …
-
AstraZeneca Q1 Earnings Rise, But China Drug Allegations May Lead To $8 Million Penalty
29 Apr 2025 14:45 GMT
… New Order Targets Drug Pricing Transparency And Medicare Cost Reduction
Cardiovascular … to $2.08 billion.
Symbicort revenues fell 6% (-3% CER … CAPItello-280 Phase 3 trial of Truqap (capivasertib) in … the comparator arm upon trial completion.
Price Action: AZN …